Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18768920 | BACILLUS VELEZENSIS COMPOSITIONS AND METHODS OF USE THEREOF | July 2024 | February 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18744293 | METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES | June 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18620483 | Method and System to Modify an Individual�s Gut-Brain Axis to Provide Neurocognitive Protection | March 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18615672 | Modulation of an Individual's Gut Microbiome to Address Osteoporosis and Bone Disease | March 2024 | March 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18559543 | CANCER THERAPY WITH LIVE ATTENUATED BACTERIA | November 2023 | October 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18489869 | METHODS FOR IMPROVING SKIN CONDITION, HAIR HEALTH, ANTI-INFLAMMATION ACTIVITY, CARDIOVASCULAR HEALTH, ANTI-OXIDATION ACTIVITY, ANTI-AGING ACTIVITY, AND/OR RELIEVING BODY FATIGUE BY USING YEAST POWDER RICH IN NICOTINAMIDE MONONUCLEOTIDE | October 2023 | June 2025 | Allow | 20 | 1 | 0 | No | No |
| 18243566 | METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES | September 2023 | June 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18455329 | BIFIDOBACTERIUM LONGUM NCIMB 41676 | August 2023 | June 2025 | Allow | 21 | 1 | 0 | No | No |
| 18453684 | VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS | August 2023 | July 2024 | Allow | 11 | 1 | 0 | No | No |
| 18232433 | Probiotic Method and Composition for Maintaining a Healthy Vaginal Microbiome | August 2023 | January 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18336974 | MEDICAL CELL CMU-pb-7 AND APPLICATION THEREOF IN PREPARATION OF ANTIOXIDANT DRUGS | June 2023 | August 2024 | Abandon | 14 | 2 | 0 | No | No |
| 18295874 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | April 2023 | May 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18149950 | PSEUDOMONAS MONTEILII STRAIN AND APPLICATION THEREOF IN THE DEGRADATION OF PETROLEUM HYDROCARBONS IN SALINE-ALKALI ENVIRONMENT | January 2023 | February 2024 | Allow | 13 | 1 | 1 | No | No |
| 18057333 | MONOCLONAL ANTIBODY AGAINST D-DIMER AND DIAGNOSIS AGENT FOR DETECTING D-DIMER, CROSSLINKED FIBRIN AND ITS DERIVATIVES CONTAINING D-DIMER BY USING THE ANTIBODY | November 2022 | June 2025 | Allow | 30 | 1 | 0 | No | No |
| 17986286 | Methods Of Vaccine Administration | November 2022 | January 2025 | Allow | 26 | 1 | 0 | Yes | No |
| 18049704 | METHODS TO SPATIALLY PROFILE PROTEASE ACTIVITY IN TISSUE AND SECTIONS | October 2022 | February 2025 | Allow | 27 | 1 | 0 | No | No |
| 18047586 | Virulence Attenuated Bacteria Based Protein Delivery | October 2022 | January 2025 | Allow | 27 | 1 | 0 | Yes | No |
| 17934166 | ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF | September 2022 | November 2024 | Allow | 25 | 1 | 0 | No | No |
| 17932685 | PNEUMOCOCCAL FUSION PROTEIN VACCINES | September 2022 | June 2024 | Allow | 21 | 0 | 0 | Yes | No |
| 17931876 | SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION | September 2022 | January 2025 | Allow | 28 | 2 | 0 | No | No |
| 17819199 | ANTI-O2 ANTIBODIES AND USES THEREOF | August 2022 | January 2025 | Allow | 29 | 1 | 0 | No | No |
| 17869055 | IMMUNOGENIC COMPOSITION COMPRISING STAPHYLOCOCCAL ANTIGENS | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17862282 | TREATMENT OF DIABETES AND CHRONIC PANCREATITIS USING BOTULINUM TOXIN | July 2022 | November 2023 | Allow | 16 | 2 | 0 | No | No |
| 17789149 | ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION COMPRISING PROBIOTICS AND ANTIBIOTICS, AND METHOD USING SAME | June 2022 | April 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17784690 | CRYPTOSPORIDIOSIS VACCINE | June 2022 | July 2025 | Allow | 37 | 1 | 1 | No | No |
| 17750083 | TREATING AND PREVENTING MICROBIAL INFECTIONS | May 2022 | June 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17748875 | TREATING AND PREVENTING MICROBIAL INFECTIONS | May 2022 | June 2023 | Allow | 13 | 2 | 0 | No | No |
| 17747689 | ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF | May 2022 | November 2024 | Allow | 30 | 1 | 0 | No | No |
| 17728793 | TREATING AND PREVENTING MICROBIAL INFECTIONS | April 2022 | February 2023 | Allow | 9 | 1 | 0 | No | No |
| 17660558 | LIVE ATTENUATED ORAL VACCINE AGAINST SHIGELLOSIS AND TYPHOID FEVER | April 2022 | May 2025 | Allow | 36 | 1 | 0 | No | No |
| 17709277 | BACILLUS SUBTILIS STRAINS IMPROVING ANIMAL PERFORMANCE PARAMETERS | March 2022 | March 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17656903 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | March 2022 | January 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17656897 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS | March 2022 | August 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17655687 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT OF INFECTIOUS DISEASES OR INFLAMMATORY DISEASES | March 2022 | December 2024 | Allow | 33 | 1 | 0 | No | No |
| 17695569 | ANTIBODY MOLECULES AND USES THEREOF | March 2022 | October 2024 | Allow | 31 | 0 | 0 | Yes | No |
| 17670818 | METHODS OF DETECTION OF COMPOUND, ANTIBODY OR PROTEIN USING RECOMBINANT ENDOSPORES OR BACTERIA AS SENSING ELEMENT | February 2022 | April 2025 | Allow | 38 | 1 | 1 | No | No |
| 17665130 | PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS | February 2022 | March 2023 | Allow | 13 | 2 | 0 | No | No |
| 17589484 | UNIVERSAL VACCINES AGAINST IMMUNOGENS OF PATHOGENIC ORGANISMS THAT PROVIDE ORGANISM-SPECIFIC AND CROSS-GROUP PROTECTION | January 2022 | February 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17569377 | BINDING MOIETIES FOR BIOFILM REMEDIATION | January 2022 | July 2024 | Allow | 30 | 1 | 0 | No | No |
| 17645344 | COMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASE | December 2021 | January 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17554531 | PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS | December 2021 | November 2024 | Allow | 35 | 1 | 0 | No | No |
| 17547211 | METHODS OF TREATMENT FOR CERVICAL DYSTONIA | December 2021 | November 2024 | Allow | 35 | 1 | 0 | No | No |
| 17545486 | ANTI-GALACTOFURANOSE ANTIBODIES FOR DETECTING AND TREATING ASPERGILLOSIS | December 2021 | December 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17505048 | ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS | October 2021 | December 2022 | Abandon | 13 | 1 | 1 | Yes | No |
| 17502320 | METHOD FOR LATERAL FLOW IMMUNOASSAY | October 2021 | March 2024 | Allow | 29 | 1 | 0 | No | No |
| 17503032 | METHODS OF TREATMENT OF INFECTIONS USING BACTERIA | October 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17498136 | ANTI-PHYTOPATHOGENIC COMPOSITIONS | October 2021 | June 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17497295 | MULTIPLE VIRAL ANTIGEN COVID VACCINE AND THERAPEUTIC | October 2021 | June 2022 | Allow | 9 | 1 | 0 | No | No |
| 17490735 | Anti-CD47 monoclonal antibody and use thereof | September 2021 | April 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17411067 | Preparation method of yeast powder rich in nicotinamide mononucleotide, yeast powder, and methods for improving skin condition, hair health, antiinflammation, cardiovascular health, antioxidation, antiaging and/or relieving body fatigue | August 2021 | August 2023 | Allow | 24 | 0 | 0 | No | No |
| 17402220 | CHEMICAL SENSOR DEVICE AND CHEMICAL SENSOR MODULE | August 2021 | May 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17397474 | ANTI-O1 ANTIBODIES AND USES THEREOF | August 2021 | February 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17391103 | CD40 LIGAND FUSION PROTEIN VACCINE | August 2021 | November 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17389982 | STAPHYLOCOCCUS PSEUDINTERMEDIUS VIRULENCE FACTOR COMPOSITIONS | July 2021 | May 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17382426 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | July 2021 | April 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17371449 | Production of Soluble Recombinant Proteins without N-Terminal Methionine in E-Coli | July 2021 | August 2024 | Allow | 37 | 1 | 0 | No | No |
| 17368494 | COMPOSITION AND METHODS FOR MICROBIOTA THERAPY | July 2021 | December 2022 | Allow | 17 | 3 | 1 | Yes | No |
| 17305236 | VACCINE FOR PROTECTION AGAINST ETEC-INDUCED DIARRHEA COMPRISING DMLT | July 2021 | October 2023 | Allow | 28 | 1 | 1 | No | No |
| 17346452 | BRACHYURY DELETION MUTANTS, NON-YEAST VECTORS ENCODING BRACHYURY DELETION MUTANTS, AND THEIR USE | June 2021 | February 2024 | Allow | 32 | 1 | 0 | No | No |
| 17343901 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROLOGICAL OR MENTAL DISORDERS COMPRISING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEI | June 2021 | January 2023 | Allow | 19 | 2 | 1 | No | No |
| 17297923 | SYSTEM AND METHOD FOR INTEGRATION OF BIOLOGICAL CHIPS | May 2021 | June 2024 | Allow | 37 | 1 | 0 | No | No |
| 17328657 | PROCESS FOR PREPARING PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES | May 2021 | January 2025 | Allow | 44 | 1 | 0 | No | No |
| 17291010 | NUCLEIC ACID SEQUENCE MEASUREMENT DEVICE | May 2021 | October 2024 | Allow | 42 | 1 | 0 | No | No |
| 17287238 | NEW PROBIOTICS USEFUL FOR ERADICATING HELICOBACTER PYLORI INFECTION | April 2021 | February 2024 | Allow | 34 | 1 | 0 | Yes | No |
| 17226148 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | April 2021 | April 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17223710 | Microbiome-based informed method to formulate live biotherapeutics | April 2021 | March 2022 | Allow | 11 | 1 | 0 | No | No |
| 17223754 | Microbiome-based informed method to formulate live biotherapeutics | April 2021 | May 2022 | Allow | 14 | 2 | 0 | No | No |
| 17280708 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY AND RELATED DISORDERS | March 2021 | October 2023 | Allow | 31 | 2 | 0 | No | No |
| 17210957 | METHODS FOR TESTING SKIN SAMPLES | March 2021 | October 2023 | Allow | 31 | 2 | 0 | No | No |
| 17208797 | EDIBLE VACCINATION AGAINST MICROBIAL PATHOGENS | March 2021 | March 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17277138 | IMMUNOLOGICAL ADJUVANT AND VACCINE COMPOSITION INCLUDING STING AGONIST | March 2021 | January 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17275401 | HOST BACTERIUM SPECIFIC NANOPARTICLE | March 2021 | December 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 17199106 | TREATING AND PREVENTING MICROBIAL INFECTIONS | March 2021 | July 2022 | Allow | 16 | 2 | 0 | No | No |
| 17184242 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | February 2021 | May 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17175925 | NANOVESICLE DERIVED FROM PROTEUS GENUS BACTERIA, AND USE THEREOF | February 2021 | September 2023 | Allow | 31 | 1 | 0 | No | No |
| 17264821 | ORALLY ADMINISTERED SUPPLEMENTS AND METHODS OF REDUCING ABSORPTION OF CALORIES AND MODIFYING THE NUTRITIONAL VALUES OF CONSUMED NUTRIENTS | January 2021 | December 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17159595 | PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS | January 2021 | June 2021 | Allow | 5 | 1 | 0 | No | No |
| 17156477 | MYCOPLASMA VACCINES AND USES THEREOF | January 2021 | November 2024 | Allow | 46 | 2 | 1 | Yes | Yes |
| 17261532 | FECAL MICROBIOTA COMPOSITION FOR USE IN REDUCING TREATMENT-INDUCED INFLAMMATION | January 2021 | February 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17148592 | METHOD FOR TESTING ECOTOXICITY OF DISINFECTION BY-PRODUCTS | January 2021 | September 2023 | Allow | 32 | 0 | 0 | Yes | No |
| 17259889 | TREATMENT METHODS AND COMPOSITIONS | January 2021 | January 2024 | Allow | 36 | 2 | 0 | Yes | No |
| 17140832 | METHOD OF ATTACKING TARGET CELLS | January 2021 | August 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17256428 | METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES | December 2020 | October 2023 | Allow | 34 | 1 | 0 | No | No |
| 17132624 | SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION | December 2020 | May 2022 | Allow | 17 | 2 | 0 | No | No |
| 17121621 | MSP NANOPORES AND RELATED METHODS | December 2020 | December 2022 | Allow | 24 | 3 | 0 | Yes | No |
| 17251973 | ESCHERICHIA COLI 0157:H7 PROTEINS AND USES THEREOF | December 2020 | August 2022 | Abandon | 20 | 1 | 1 | No | No |
| 17104456 | METHOD FOR INCREASING ETEC CS6 ANTIGEN PRESENTATION ON CELL SURFACE AND PRODUCTS OBTAINABLE THEREOF | November 2020 | July 2023 | Allow | 32 | 1 | 0 | No | No |
| 17058978 | DYNAMIC CLAMPS AND METHODS OF USE THEREOF | November 2020 | November 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 17058277 | Colloidal Particles Functionalized Homogeneously by Biomolecules | November 2020 | December 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 17098021 | ANTIBODIES FOR PREVENTION, TREATMENT AND DIAGNOSIS OF P.GINGIVALIS INFECTION | November 2020 | October 2022 | Allow | 23 | 1 | 1 | No | No |
| 17096890 | METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES | November 2020 | June 2023 | Allow | 32 | 0 | 1 | No | No |
| 17089172 | IMMUNOSTIMULATORY COMPOSITIONS | November 2020 | September 2023 | Allow | 34 | 1 | 0 | No | No |
| 17051993 | TUBERCULOSIS VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF | October 2020 | June 2022 | Allow | 20 | 1 | 0 | No | No |
| 16949415 | ANTI-PD-L1 ANTIBODY FOR DETECTING PD-L1 | October 2020 | February 2023 | Allow | 28 | 2 | 1 | Yes | No |
| 17082008 | NANO-VESICLES DERIVED FROM GENUS MORGANELLA BACTERIA AND USE THEREOF | October 2020 | October 2023 | Allow | 35 | 1 | 1 | No | No |
| 17073879 | ANTI-PSEUDOMONAS PSL BINDING MOLECULES AND USES THEREOF | October 2020 | July 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17068173 | IMMUNOGENIC COMPOSITIONS COMPRISING LAWSONIA INTRACELLULARIS | October 2020 | February 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17061687 | Bioconjugates Made From Recombinant N-Glycosylated Proteins From Procaryotic Cells | October 2020 | September 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 17039255 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | September 2020 | June 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17037455 | ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF | September 2020 | June 2022 | Allow | 20 | 5 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JACKSON-TONGUE, LAKIA J.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JACKSON-TONGUE, LAKIA J works in Art Unit 1645 and has examined 735 patent applications in our dataset. With an allowance rate of 66.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner JACKSON-TONGUE, LAKIA J's allowance rate of 66.5% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JACKSON-TONGUE, LAKIA J receive 2.12 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JACKSON-TONGUE, LAKIA J is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +18.7% benefit to allowance rate for applications examined by JACKSON-TONGUE, LAKIA J. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 23.5% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 44.0% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 84.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 63% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 78.6% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 68.0% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 4.1% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.